Table 2. Circulating miR-21-5p and miR-126-3p levels in T2DM patients with different diabetic complications.
MiR-21 levels | |||
---|---|---|---|
Diabetes complications | Patients with a specific complication vs. all the other patients | Mean ± SD | p |
neuropathy | 37 vs. 156 | 0.21±0.27 vs. 0.34±0.39 | 0.089 |
nephropathy | 27 vs. 166 | 0.26±0.28 vs. 0.33±0.39 | 0.489 |
chronic renal failure | 10 vs. 183 | 0.39±0.41 vs. 0.31±0.38 | 0.375 |
retinopathy | 84 vs. 109 | 0.27±0.30 vs. 0.35±0.43 | 0.165 |
lower limb arteriopathy | 11 vs. 182 | 0.37±0.33 vs. 0.31±0.38 | 0.534 |
MACE | 56 vs. 137 | 0.46±0.44 vs. 0.26±0.33 | <0.001 |
MiR-126 levels | |||
neuropathy | 37 vs. 156 | 0.18±0.20 vs. 0.24±0.22 | 0.122 |
nephropathy | 27 vs. 166 | 0.20±0.16 vs. 0.23±0.22 | 0.512 |
chronic renal failure | 10 vs. 183 | 0.23±0.19 vs. 0.23±0.22 | 0.993 |
retinopathy | 84 vs. 109 | 0.23±0.20 vs. 0.23±0.23 | 0.863 |
lower limb arteriopathy | 11 vs. 182 | 0.23±0.21 vs. 0.29±0.24 | 0.351 |
MACE | 56 vs. 137 | 0.21±0.21 vs. 0.28±0.22 | 0.032 |
ANCOVA adjusted for age, sex, and number of complications. Levels lower than 0.05 in bold.